---
title: "BTIG Remains a Buy on Dynex Capital (DX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284053488.md"
description: "BTIG analyst Eric Hagen has maintained a Buy rating on Dynex Capital (DX) with a price target of $16.00. Hagen, a 3-star analyst, has an average return of 2.7% and a 49.46% success rate. Dynex Capital also received a Buy rating from KBW’s Bose George on April 21, while UBS assigned a Hold rating today."
datetime: "2026-04-24T20:45:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284053488.md)
  - [en](https://longbridge.com/en/news/284053488.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284053488.md)
---

# BTIG Remains a Buy on Dynex Capital (DX)

BTIG analyst Eric Hagen maintained a Buy rating on Dynex Capital today and set a price target of $16.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Hagen is a 3-star analyst with an average return of 2.7% and a 49.46% success rate. Hagen covers the Real Estate sector, focusing on stocks such as Annaly Capital, Rithm Capital, and AGNC Investment.

In addition to BTIG, Dynex Capital also received a Buy from KBW’s Bose George in a report issued on April 21. However, today, UBS assigned a Hold rating to Dynex Capital (NYSE: DX).

### Related Stocks

- [DX.US](https://longbridge.com/en/quote/DX.US.md)

## Related News & Research

- [Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks With Over 15% Dividend Yields](https://longbridge.com/en/news/286766752.md)
- [Assessing Dynex Capital (DX) Valuation After Q1 EPS Miss And New Share Repurchase Program](https://longbridge.com/en/news/286164501.md)
- [BTIG Sticks to Its Buy Rating for Dick’s Sporting Goods (DKS)](https://longbridge.com/en/news/286253986.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)